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The global burden of cardiovascular disease is significant. In 2015, there were an estimated 17.9 
million deaths attributable to cardiovascular disease worldwide.1 Whilst age-standardised 
cardiovascular disease mortality has declined over the past decade, the absolute number of deaths 
attributable to cardiovascular disease has risen by 12.5%.1 Reliably predicting future cardiovascular 
disease is therefore an important public health priority. This is especially relevant for low- and 
middle-income countries, which bear the majority of cardiovascular disease burden2,3 due to a high 
prevalence of both traditional and non-traditional cardiovascular risk factors.4,5 
 
Numerous cardiovascular disease risk assessment models have been developed in the past five 
decades. The majority of these have focused on the prediction of incident cardiovascular disease in 
the general population.6 This is despite reports that almost half of cardiovascular disease events occur 
in individuals with a history of prior cardiovascular disease.7 Indeed, such patients have a 20% higher 
absolute risk of cardiovascular disease events than patients with no history of prior cardiovascular 
disease. In this issue of Heart, Poppe and colleagues8 tackle in an important research gap, describing 
the development and validation of a cardiovascular disease risk prediction model for patients with a 
history of prior cardiovascular disease.  
 
Many national guidelines do not advocate the risk assessment of patients with a history of prior 
cardiovascular disease events.9,10 At first glance this seems reasonable, because such patients are 
already deemed to be at a high-risk of future cardiovascular events. Therefore, the substantial risk 
experienced by these individuals is essentially considered non-modifiable. However, the problem 
with this approach is that it may disincentivise the active management of contributory, modifiable 
risk factors (e.g. smoking cessation), or lead to poor compliance with preventative pharmacotherapies 
due to perceived futility. Both of these factors are likely to contribute to an increased cardiovascular 
disease burden in this population, resulting in poorer patient outcomes. 
 
The authors first identified a ‘derivation’ cohort of over 13,000 primary care patients recruited to the 
PREDICT database who had previously been diagnosed with acute coronary syndrome (Figure 1).11 
Using routinely-collected, linked national healthcare data, patients were automatically followed-up 
for cardiovascular events (defined as hospital admissions due to acute coronary syndrome, heart 
failure, stroke or peripheral vascular disease; or death from cardiovascular causes), which were then 
used to inform the development of a cardiovascular disease risk prediction score. This predictive 
model was then validated on the Coronary Disease Cohort Study (CDCS) cohort, which recruited 
patients with acute coronary syndrome attending Christchurch or Auckland City hospitals (New 
Zealand) between 2002 and 2009. Overall, the predictive model performed equally well in both real-
world settings. 
 
Usefully, the predictive model contained only variables that were pre-specified by Poppe and 
colleagues to ensure they were both clinically relevant and routinely available in clinical practice. 
The strongest predictors of a recurrent cardiovascular disease event within 5 years were age 60 years 
or older (especially age 70 – 79 years), deprivation (especially being in the most deprived quintile), 
and history of heart failure, poorly controlled diabetes (HBA1c ≥65 mmol/mol) or renal impairment 
(serum creatinine ≥ 150 μmol/L). The importance of time since prior acute coronary syndrome on the 
subsequent risk of a recurrent cardiovascular disease event was also recognised by the authors. 
Notably, patients evaluated within 1 year of their initial acute coronary syndrome event were at the 
highest risk of recurrence.  
 
Crucially, the patient cohorts utilised by Poppe and colleagues are contemporaneous, which reduces 
the likelihood of their predictive model over-estimating cardiovascular disease risk. This is a problem 
often associated with the development and validation of predictive models using historic patient 
cohorts, which have an inherently higher baseline risk due to a decline in the incidence of 
cardiovascular disease and improved survival following cardiovascular events over the last three 
decades.12,13 Therefore, as the authors point out, the derivation cohort is likely to be representative of 
the type of patient routinely evaluated in primary care in New Zealand in the current era.  
 
Poppe and colleagues should be commended for following best practice with regards to the 
development and reporting of a risk prediction model and especially for externally validating their 
model in a separate cohort of patients.14 Indeed, this is a step that only a minority of published studies 
have performed.6 The impressive performance of their predictive model in the validation cohort, 
which comprised mostly of European patients, also suggests that some of the concern regarding the 
model’s external applicability may be unfounded.  
 
Further, the authors should be commended for utilising the sound statistical principles outlined by 
Royston et al.15 These include the incorporation of a baseline survival hazard and the centring of the 
prognostic index from the derivation cohort on the mean prognostic index in the transformation of 
multivariable relative risk to absolute risk. Similar methodological approaches have been shown to 
improve model performance in the primary prevention setting and accordingly they improved the  
performance of the model derived by Poppe and colleagues in the present study.8,16 Future research 
should build on this impressive work by focusing on the external validation of this predictive model 
in contemporary cohorts from distinct geographical regions. 
 
In summary, Poppe and colleagues have demonstrated that risk prediction research is undergoing a 
paradigm shift in patients with a history of prior cardiovascular disease. Using contemporary, 
routinely-collected clinical data, they have developed, validated and reported a cardiovascular disease 
risk prediction model specifically for use in patients with a history of acute coronary syndrome. The 
resultant model was clinically relevant and performed well at predicting cardiovascular disease risk 
in this important population of patients. However, whether it will perform equally well in other case 
mixes, whilst avoiding subsequent under- or over-treatment, and translate to improved patient 
outcomes, are exciting and as yet unanswered questions.  
 
Figure 1: Map summarising linkage of national data assets utilised by Poppe and colleagues to define 
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